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Abstract
Introduction Ankylosing spondylitis (AS) and inflammatory
bowel disease (IBD) share similarities and are classified as
spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae
antibody (ASCA), anti-I2 (associated with anti-Pseudomonas
activity), anti-Escherichia coli outer membrane porin C (anti-
OmpC), anti-flagellin (anti-CBir1), and antineutrophil
cytoplasmic antibodies (ANCA) possess clinical significance.
Because of the overlap between the two conditions, a pilot
study was designed to compare the frequency of these
antibodies in AS patients compared to normal controls.
Methods Serum stored from 80 AS patients and 80 control
subjects was available for analysis. ASCA, anti-I2, anti-OmpC,
anti-CBir1, and ANCA studies were completed on all serum
samples using Enzyme-Linked Immunosorbent Assay (ELISA)
methodology. The following analyses were performed:
comparison of positivity based on the established values in IBD,
median values, the number of subjects in each serology in the
4th quartile of a normal distribution, and the mean quartile sum of
all the antibodies.
Results There was no difference in positivity rates between AS
and control groups with the established IBD values. The median
anti-I2 response was significantly higher in AS than in controls
(11.78 vs 7.86, p = 0.017). Significantly more AS patients had
quartile scores of 4 for the following antibody responses: ASCA
IgG (26% vs 13%, p = 0.016, OR = 2.49, CI 1.168 - 5.313),
ASCA IgG and IgA (27% vs 12%, p = 0.006, OR = 2.9, CI:
1.342 - 6.264), and anti - I2 (25% vs 14%, p = 0.0424, OR =
2.15, CI: 1.018 - 4.538). The mean quartile sum of the antibody
responses was elevated in AS patients when ANCA was
excluded (10.526 vs 9.519, p = 0.03). When ANCA was
included, this difference lost significance.
Conclusions The data from this pilot study points towards
mucosal dysregulation as an important pathway in AS. We were
able to demonstrate that anti-I2 could play a pathologic role in
AS. The elevated mean total antibody response being significant
only with ANCA exclusion is consistent with the
histopathological evidence that intestinal inflammation in AS is
similar to Crohn's disease. To better define the roles of these
antibodies in AS, larger studies with more precisely defined
patient characteristics are required.
Introduction
Ankylosing spondylitis (AS), an inflammatory disease of
unknown etiology, is characterized by a progressive and
destructive inflammatory arthritis of the spine, peripheral joints,
and entheses, sometimes with extra-spinal manifestations. A
recent review of the epidemiology of AS in the USA indicates
that the prevalence is 0.52%, with the prevalence of overall
spondyloarthritides ranging from 0.34 to 1.31% depending on
diagnostic criteria [1]. The distinguishing pathologic aspect of
AS is the presence of reactive bone growth forming syn-
desmophytes, and these features are associated with ankylo-
sis of articulating structures causing limited mobility, abnormal
posture, and increased fracture risk [2]. Extra spinal disease
secondary to AS includes uveitis, cardiac valve dysfunction,
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renal disease due to secondary amyloidosis, and microscopic
intestinal inflammation [3].
AS is considered to be part of a larger group of disorders
known as the spondyloarthritides that includes inflammatory
bowel disease (IBD), which is usually classified as Crohn's
disease (CD) or ulcerative colitis (UC) depending on the
inflammatory pattern. Although intestinal inflammation pre-
dominates in patients with IBD, some patients possess axial
arthritis affecting the spine and sacroiliac joints that can be
indistinguishable from AS. For example, it has been observed
that 10 to 20% of patients with IBD have sacroiliac changes
and 7 to 12% of patients have a concomitant diagnosis of AS,
a rate approximately 10 times that of the non-IBD population
[4]. To further support this relation between AS and IBD,
investigators have noted that a significant percentage of
patients with AS also have intestinal inflammation. Of patients
with AS, 26% have histopathological intestinal inflammation
consistent with CD, and 6.5 to 10% possess a diagnosis of
IBD [3]. Furthermore, similar genetic predisposition is shared
by these two diseases. Both patients with AS and IBD have an
increased prevalence of human leukocyte antigen (HLA)-B27,
85% and 33%, respectively [4], and, more recently, the IL23R
gene has been shown to be associated with both IBD and AS
[5,6].
CD is associated with a selected loss of tolerance to commen-
sal microbiota as evidenced by circulating antibodies to a sub-
set of microbial antigens [7], including anti-Saccharomyces
cerevisiae  antibody (ASCA), anti-I2 (associated with anti-
Pseudomonal activity), anti-Escherichia coli outer membrane
porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineu-
trophil cytoplasmic antibodies (ANCA). Previous studies have
shown evidence of loss of tolerance by exhibiting elevated
ASCA IgA levels in AS patients [8,9]. This finding, however, is
not always replicated [10].
Because of the IBD-like mucosal changes that occur in a sub-
stantial percentage of AS patients, we hypothesized that sero-
logic activity normally used to detect loss of tolerance to
enteric antigens related to mucosal dysregulation in IBD will
be detectable in levels above normal controls in AS patients.
To determine whether AS and CD or IBD have similar abnor-
malities in loss of mucosal tolerance, we tested antibody reac-
tivity to these microbial antigens in a pilot exploratory study
with a limited number of patients to see if a signal indicating
further, more comprehensive testing would be warranted.
Materials and methods
Patient selection
Eighty patients were randomly selected from the Prospective
Outcomes in Ankylosing Spondylitis (PSOAS) cohort, an AS
cohort previously assembled from patients from Cedars-Sinai
Medical Center, University of Texas at Houston, National Insti-
tutes of Health, and the University of California at San Fran-
cisco [11,12]. All patients are 18 years of age or older and
have supplied written consent to be a part of the cohort and
related studies. These patients meet the modified New York
criteria for AS: low back pain and stiffness for more than three
months which improves with exercise but is not relieved by
rest OR limitation of the lumbar spine in the sagittal and frontal
planes OR limitation of chest expansion relative to normal val-
ues corrected for age and sex AND erosions and ankylosis of
at least one sacro-iliac joint or sclerosis in the bilateral sacro-
iliac joints [13]. If a selected sample was from a patient with
IBD by self-report, another sample was selected. Eighty con-
trol patients whose serum was already collected and stored at
-70°F in Houston, Texas, were used. These patients are 18
years of age or older, have supplied written consent, and are
free from rheumatic disease. The size of the group was deter-
mined to power the study to detect a statistically significant
difference if the frequency of positivity for any single serology
was 15% in the AS group and 5% in the control group. The
study was approved by the Institutional Review Board at all
participating centers.
Laboratory methods
The samples were collected and re-labeled to blind laboratory
personnel to their source. All serologic tests were run on the
samples at the same time in an effort to decrease variance.
The basic laboratory methods for the determination of each
serology have been described elsewhere [7,14]. Sera was
tested by ELISA for the five individual serologies: ANCA,
ASCA IgG and IgA, Anti-I2, Anti-OmpC, and Anti-CBir1. The
results of each assay are expressed in ELISA units and reflect
antibody activity except for ASCA. ASCA results were log
transformed prior to quartile distribution.
After the testing was complete and the antibody activity levels
determined, the results were unblinded to determine their ori-
gin. The groups were compared using the following statistical
methodologies.
Statistical methods
In the first analysis, chi-squared testing was performed to com-
pare the positivity rates for each separate serology in AS
patients versus controls. The reference values usually applied
to IBD were used (Table 1). Next, the Wilcoxin Rank test was
performed to compare the median quantitative antibody level
between cases and controls.
For the next analysis, a distribution of the magnitude of each
serologic response for all subjects was divided into four quar-
tiles. A score of 1 to 4 was assigned on the basis of the des-
ignated quartile (<25% = 1; 25 to 50% = 2; 51 to 74% = 3;
75 to 100% = 4). Chi-squared testing was performed to com-
pare the percentage of cases and controls with a score of 4
versus 1, 2, or 3. Chi-squared testing was repeated to com-
pare cases and controls with a score of 3 and 4 versus 1 and
2. To determine the significance of increasing odds ratio (OR)Available online http://arthritis-research.com/content/11/6/R177
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for AS with increasing quartile score for each antibody, the
Cochran-Armitage test was performed. For the OR calcula-
tions, the minimum quartile score of 1 was set as the baseline,
that is, an OR of 1.0. In the final analysis, student t-test was
performed to compare the mean quartile sum between cases
and controls. All the analyses were performed by SAS compu-
ter software (version 9.13; SAS Institute, Inc., Cary, NC, USA).
Results
Seventy nine patients each from both the AS and normal con-
trol groups yielded results suitable for analysis. The demo-
graphic information for each group is in Table 2. When the
reference ranges for IBD are applied, there is no difference in
the positivity rates between AS patients and controls (Table
3).
However, when comparing the median level of the antibody
r e s p o n s e  o f  e a c h  s e r o l o g y  i n  A S  p a t i e n t s  v e r s u s  c o n t r o l s
(Table 4), anti-I2 levels were significantly elevated in AS
patients (11.78 vs. 7.86, P = 0.017).
Given the suggestion that there were differences between
controls and AS subjects in the level of antibody responses,
we performed a more extensive analysis using approaches
that have been used in evaluating these responses in IBD
[7,14-16]. The antibody results of the patients and controls
were distributed and divided into quartiles (Figure 1). Subjects
with AS were more likely to have a quartile score of 4 (upmost
quartile) for anti-I2, ASCA IgG, and total ASCA (IgG + IgA)
(Figure 2). The analysis was repeated to determine if there
were serologies that had higher numbers of AS patients with
a quartile score of 3 and 4 combined. Only anti-I2 yielded a
significant difference (62% AS patients vs 39% controls, OR
= 2.67, confidence interval (CI) = 1.403 to 5.072, P = 0.003).
Finally, we compared the quartile sum of all serologies in AS
versus controls. The level of each antibody was normalized by
dividing the cohort into quartiles. The overall level of response
to the antibodies was measured by summing the individual
quartiles to yield a quartile sum. The elevated mean quartile
sum seen in AS patients was higher than controls when ANCA
was excluded (10.526 vs 9.519, P = 0.03). When ANCA was
Table 1
Reference values for antibodies tested and their values in Crohn's disease
Antibody Positive cutoff reference value Median value in CD, Range Percent positive in CD
ASCA IgG 20 EU 26.9, 0-415.2 38.1%
ASCA IgA 40 EU 12.5, 0-164 38.1%
Anti-I2 30 EU 18.9, 0-324.1 46.8%
Anti-OmpC 23 EU 15.2, 0-296.4 31.7%
Anti-CBir1 30 EU 26.1, 0-279.7 49%
ANCA 30 EU 1.4-277.7* 74%*
The positive cutoff value is two standard deviations above the mean value in healthy controls. *These values apply to ulcerative colitis as opposed 
to crohn's disease.
ANCA = antineutrophil cytoplasmic antibodies; anti-CBir1 = anti-flagellin; anti-OmpC = anti-Escherichia coli outer membrane porin C; ASCA = 
Anti-Saccharomyces cerevisiae antibody; CD = Crohn's disease; EU = ELISA units.
Table 2
Demographic information for AS patients and controls
AS patients Controls
Age in years (mean, range) 36.5, 19-61 30.8, 18-104
Disease duration in years (mean, range) 10.3, 0.12-43 Not applicable
Male (%) 62% 42%
HLA B27 (%) 84% Not available
Ethnicity Caucasian 80%
African American 2.5%
Asian 3.8%
Hispanic 3.8%
Caucasian and Hispanic 8.8%
African American and Caucasian 1%
Caucasian 100%
HLA-B27 status for the control group was unavailable.
AS = ankylosing spondylitis; HLA = human leukocyte antigen.Arthritis Research & Therapy    Vol 11 No 6    Mundwiler et al.
Page 4 of 7
(page number not for citation purposes)
included, the difference in mean quartile sum lost significance.
Furthermore, the number of AS patients in each quartile group
increased as the quartile sum increased as shown by the
increasing ORs (group 4-6 (reference groups) vs. 7-9 vs. 10-
13 vs. 14-16: 1 vs. 1.77 vs. 1.54 vs. 3.0, P trend = 0.03). The
summary of this comparison is shown in Figure 3.
Discussion
In this pilot study, our results indicate that mucosal dysregula-
tion demonstrated by elevated antibody responses to CD-
related enteric microbial antigens is present in a cohort of AS
patients. Using a quartile analysis method that allows for a
more sensitive evaluation of levels of these CD-related micro-
bial antigens when compared with disease control cohorts, we
detected an increased individual antibody response to I2 and
ASCA, as well as a higher response to the combination of anti-
bodies in patients compared with controls.
The quartile analysis methodology has yielded significant
results in IBD studies utilizing these serologies as indicators of
mucosal dysregulation. Demonstrating the strength of this
analysis to determine differences in non-IBD but related indi-
viduals was previously demonstrated by Devlin and colleagues
[17]. Using quartile sums, the level of antibody responses in
CD patients was related to the number of NOD2 variants (0-
2) in a given individual. The same analysis was then repeated
using unaffected family members of CD patients. Although
some family members have elevated levels as defined by cut
offs used to differentiated CD from normal controls, overall the
levels were much lower than CD patients. However, when the
quartile sums were recalculated using the levels of antibodies
within entire unaffected family members as the cohort and not
CD, the same relation of numbers of NOD2 variants to quartile
sums was seen as that in the CD cohort. An important concept
from these analyses is that the current laboratory methods are
tailored to have optimal sensitivity and specificity for patients
with CD. However, there are no established reference ranges
or methods for detecting these antibody values in AS subjects.
In the future, it may be possible to develop a method to study
the AS population at large using appropriate controls.
In addition, we observed that the sum of antibody activity is
higher in AS patients compared with controls if ANCA is
excluded. In our study, ANCA levels in AS patients were not
significantly elevated when compared with controls. In IBD
studies where these issues are addressed, pANCA (perinu-
clear ANCA) positivity is most typically associated with UC as
opposed to CD [18]. This finding from our study is consistent
with clinical observations that intestinal inflammation associ-
ated with AS more closely resembles the phenotype of CD
rather than UC [4]. Thus, our pattern of serological detection
is consistent with what is hypothesized about the relation
between AS and CD.
In IBD, detecting the loss of tolerance to certain antigens has
diagnostic and prognostic significance. For example, deter-
mining the pANCA and ASCA status of IBD patients helps
determine if the patient's phenotype will be more consistent
with CD or UC with a high specificity [18]. Furthermore, a
pANCA antibody response in a CD patient signifies a predilec-
tion towards left-sided large intestine involvement [19]. Out-
Table 3
Positivity rates of serologies in AS patients and controls
Antibody Positive AS patients Positive controls P value
IgA ASCA 1.3% (1) 0% (0) 1.0
IgG ASCA 3.8% (3) 1.3% (1) 0.62
Anti-I2 12.7% (10) 5.1% (4) 0.09
Anti-OmpC 3.8% (3) 2.5% (2) 1.0
Anti-CBir1 17.7% (14) 11.4% (9) 0.25
ANCA 6.35 (5) 5.1% (4) 1.0
Normal cut-offs normally utilized in IBD applied here.
ANCA = antineutrophil cytoplasmic antibodies; anti-CBir1 = anti-
flagellin; anti-OmpC = anti-Escherichia coli outer membrane porin C; 
AS = ankylosing spondylitis; ASCA = Anti-Saccharomyces 
cerevisiae antibody.
Table 4
Median value of titers in AS patients versus controls and results of Z-testing
Antibody Median value of titer in AS patients Median value of titer in control patients P value
IgA ASCA 1.24 1.10 0.28
IgG ASCA 4.70 4.05 0.29
Anti-I2 11.78 7.86 0.0172
Anti-OmpC 8.61 7.70 0.30
Anti-CBir1 16.26 15.05 0.63
ANCA 11.6 12.1 0.65
The median value of Anti-I2 in AS patients is significantly increased when compared to controls (shown in bold and italics).
ANCA = antineutrophil cytoplasmic antibodies; anti-CBir1 = anti-flagellin; anti-OmpC = anti-Escherichia coli outer membrane porin C; AS = 
ankylosing spondylitis; ASCA = Anti-Saccharomyces cerevisiae antibody.Available online http://arthritis-research.com/content/11/6/R177
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come studies have revealed that anti-I2 activity is associated
with increased likelihood of fibrostenosing CD, that anti-
OmpC activity is associated with increased likelihood of per-
foration, and patients with loss of tolerance to multiple anti-
gens are more likely to undergo small bowel surgery [15].
Additionally, anti-CBir1 activity is associated with penetrating,
fibrostenosing disease [16]. Further detection of these serolo-
gies have also aided in revealing that mucosal dysregulation
exists in unaffected relatives who carry genetic markers for
IBD in comparison with controls who do not [17,20].
With these findings reported herein, it is our hope that we can
make similar pathologic and clinical associations with the
presence of mucosal dysregulation and AS. Although the
cause of AS is still unknown, associating mucosal dysregula-
tion with disease onset of AS would bring us closer to poten-
tially discovering the trigger that initiates the disease
phenotype called AS. Further, as in IBD, these serologies may
help provide clinical information in AS that could indicate
which AS patients are more likely to have intestinal inflamma-
tion or even develop overt IBD. They may help determine
patients who are more likely to have aggressive disease, differ-
ent phenotypic patterns of ankylosis, or response to biologics.
There are obvious limitations to interpreting the results from
this pilot study. First, our sample size is small. A larger study is
Figure 1
Quartile distributions for anti-OmpC, anti-I2, anti-Cbir1, and ASCA IgG  and IgA Quartile distributions for anti-OmpC, anti-I2, anti-Cbir1, and ASCA IgG 
and IgA. Each colored section of the bar represents approximately 40 
patients from all the subjects in the study, both ankylosing spondylitis 
patients and controls. anti-CBir1 = anti-flagellin; anti-OmpC = anti-
Escherichia coli outer membrane porin C; ASCA = Anti-Saccharomy-
ces cerevisiae antibody.
Figure 2
AS patients versus controls for each serology with a quartile score of 4 AS patients versus controls for each serology with a quartile score of 4. Significant results are in bold. Confidence intervals for significant odds 
ratios are: ASCA IgG (1.168, 5.313), ASCA IgG and IgA (1.342, 6.264), and anti-I2 (1.018, 4.538). anti-CBir1 = anti-flagellin; anti-OmpC = anti-
Escherichia coli outer membrane porin C; ASCA = Anti-Saccharomyces cerevisiae antibody.Arthritis Research & Therapy    Vol 11 No 6    Mundwiler et al.
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required to more precisely determine the true prevalence as
well as the significance of these serologies in AS. Further-
more, these patients are a random sampling from an AS cohort
who are only characterized by the absence of IBD. Further
studies will serve to place patients in a clinical context provid-
ing disease associations with disease onset and duration, clin-
ical characteristics, disease severity, and treatment response.
Conclusions
In conclusion, this pilot study provides evidence that mucosal
dysregulation could play a significant role in AS. To better
define the significance of the findings, larger studies with more
precisely defined patient characteristics are required.
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